PMAPremarket Approval

Premarket Approval (PMA) is the FDA marketing-authorisation pathway for Class III medical devices under §515 of the Federal Food, Drug + Cosmetic Act, operationalised through 21 CFR Part 814. Class III, defined by §513 of the Act + 21 CFR 860.3, comprises devices that are purported or represented to be for a use in supporting or sustaining human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury — and for which general controls + special controls cannot provide reasonable assurance of safety + effectiveness. Examples include implantable defibrillators + pacemakers, mechanical heart valves, drug-eluting coronary stents, neurostimulators for therapeutic indications, breast implants, certain in-vitro diagnostics (e.g. companion diagnostics for therapeutic decision-making), and most truly novel implantable or life-supporting technologies.

A PMA application is essentially a marketing-authorisation dossier comparable in scope to a new drug NDA. It must contain valid scientific evidence including (typically) clinical-investigation data demonstrating a reasonable assurance of safety + effectiveness for the proposed indications for use in the intended patient population. The dossier covers device description, materials + components, manufacturing information sufficient to support a pre-approval inspection (PAI) of the manufacturing site, non-clinical bench + animal + biocompatibility data, software documentation per FDA software guidance + IEC 62304 where applicable, human-factors data per IEC 62366-1 + FDA HF guidance, the clinical study report from an IDE-conducted pivotal study, statistical analysis, benefit-risk determination, labelling, and a post-approval / post-market plan.

PMA approval is by Order, not by clearance letter (the latter is 510(k) language). The Order may impose conditions of approval — post-approval studies (PAS), specific labelling, MDR reporting beyond standard 21 CFR Part 803, lot tracing per §522 — that are legally binding throughout the device lifecycle. Failure to complete conditions of approval can trigger Order modification or, in extreme cases, withdrawal. The lifecycle obligations include annual reports per 21 CFR 814.84, PMA supplements per §814.39 for changes that affect safety or effectiveness, and ongoing post-market surveillance.

A device requires PMA when:

• It is classified Class III by regulation in 21 CFR Parts 862-892 + the implementing regulation has called for PMA (not all Class III devices have been called for PMA — some were grandfathered through the 1976 Medical Device Amendments + remain technically Class III but cleared via 510(k) pending FDA call-for-PMA — the §515(i) reclassification programme has progressively closed this gap).
• It is a transitional device (pre-1976) that has been called for PMA.
• It does not have a legally marketed predicate device (typically routing the sponsor to De Novo if the risk profile suggests Class I or II is appropriate; otherwise PMA is the default).
• It is a device for which the agency has issued an order requiring PMA as part of a §515(i) reclassification.

Sponsors uncertain about classification can submit a §513(g) Request for Information; certainty often comes through the Q-Submission programme (Pre-Submission) where sponsors get FDA input on classification, study design, predicate suitability + acceptable data packages before committing to a path.

Most PMA applications rely on clinical-investigation data, and most US clinical investigations of Class III devices proceed under an Investigational Device Exemption (IDE) per 21 CFR Part 812. The IDE allows sponsors to ship the investigational device in interstate commerce for clinical study without prior 510(k) clearance or PMA approval, subject to:

• An approved IDE application (significant-risk device) or abbreviated IDE requirements (non-significant-risk device — IRB-only review, no FDA submission).
• IRB approval at each investigational site.
• Informed consent from each subject per 21 CFR Part 50.
• Study conduct per 21 CFR Part 812 + the FDA / ICH GCP framework (Good Clinical Practice — 21 CFR Parts 50, 54, 56, 312 references, and the ICH E6(R3) GCP guideline).
• Adverse-event + UADE reporting on the §812.150 timeline.
• Investigator selection, training + monitoring.

The pivotal IDE study is typically a prospective, multicentre, randomised (or single-arm with pre-specified performance goal where randomisation is infeasible) study with a clinically meaningful primary endpoint, sample size powered to demonstrate safety + effectiveness in the intended-use population, and pre-specified statistical analysis plan. Sponsors should engage FDA early — typically through a Pre-Submission discussing the proposed pivotal study design — to confirm endpoint acceptability + statistical approach before committing to enrol.

21 CFR 814.20 prescribes PMA application content. The major sections:

The PMA review process:

1. Filing review (45 days) — FDA assesses whether the application is sufficiently complete to file. Refusal-to-file (RTF) is common for first-time submissions; rate has declined as eSTAR + structured submission templates have matured for PMA-track devices.
2. Substantive review — divided across reviewing disciplines (clinical, statistics, engineering, biocompatibility, sterility, microbiology, software, human factors, manufacturing, labelling, post-market). Major-deficiency letter cycle is standard; sponsors respond + FDA continues review.
3. Advisory Committee (AdCom) review — for first-of-a-kind devices, novel indications, or significant benefit-risk questions, FDA often refers the PMA to the relevant CDRH advisory committee for public discussion + vote.
4. Pre-approval inspection (PAI) of the manufacturing site(s) — FDA inspects the manufacturing facility against the QSR / QMSR + the application content; PAI findings can delay or prevent approval.
5. Approval Order — issued under §515(d) with any conditions of approval; the device may be marketed for the approved indications only.

MDUFA V (FY2023-2027) performance goals target an MDUFA decision in approximately 320 FDA days for original PMAs + various supplement classes. Actual median is typically longer (often 12-18 calendar months from initial submission for complex original PMAs) due to clock-stopping events (major-deficiency response time, AdCom scheduling, PAI scheduling, label-discussion cycles). User fees for PMAs are substantial — FY2025 standard PMA fee is approximately $540K with small-business reduction available.

After approval, any change that affects safety or effectiveness requires a PMA supplement per §814.39. The supplement types:

The change-decision framework — when a change requires which supplement vs an annual-report entry — is codified in FDA's 2008 PMA supplement decision-making guidance. Misclassifying a change (under-reporting via annual report when a supplement was required) is a common Warning Letter trigger and can result in retroactive supplement filing with potential market-action consequences.

• Conditions of approval — specific commitments in the Order (post-approval studies, registries, special labelling, lot tracing per §522, restricted distribution); legally binding and tracked by FDA.
• Annual reports per 21 CFR 814.84 — due on the anniversary of approval; summarise changes, deviations, study results, literature, label changes.
• MDR reporting per 21 CFR Part 803 — deaths within 30 days; serious injuries within 30 days; malfunctions likely to cause / contribute to death or serious injury if recurred within 30 days; 5-day reports for events requiring remedial action to prevent unreasonable risk + for events with similar 5-day investigation requirement.
• Corrections + removals reporting per 21 CFR Part 806.
• UDI per 21 CFR Part 830 — all PMA devices required to bear UDI on labelling + (where applicable) direct part marking; GUDID submission for each version + model.
• Lot tracing per §522 where the Order requires it (typically Class III implantables).
• QMSR per 21 CFR Part 820 (effective 2 Feb 2026, replacing the QSR) — design controls + production + process controls + CAPA + management responsibility across the device lifecycle.
• Post-approval studies (PAS) — pre-specified studies the sponsor commits to in the Order, with progress tracked publicly through the FDA PAS programme.
• PMA supplements for any change affecting safety or effectiveness as described above.
• Recall reporting per 21 CFR Part 7 + Part 806 — Class I, II, III recalls reported within strict timelines.

• Pivotal-study endpoint not aligned with the proposed indications — late realisation that the primary endpoint does not support the labelling claim.
• Statistical analysis plan changes post-unblinding — credibility damage; AdCom challenge.
• Bench-testing strategy does not address all expected use conditions; FDA major-deficiency letter requests additional studies that delay approval by 6+ months.
• Software documentation per FDA software guidance + IEC 62304 incomplete — particularly for SaMD components with significant clinical-decision impact.
• Human-factors validation per IEC 62366-1 + FDA HF guidance missing — particularly for home-use or lay-user devices.
• Risk-management file per ISO 14971 thin — residual-risk acceptance lacks benefit-risk reasoning per the FDA 2019 benefit-risk guidance.
• Manufacturing information insufficient to support PAI — process descriptions vague, in-process control rationale missing, supplier-control programme thin.
• PAI findings — 483 observations affecting approval; common areas are design controls (820.30) + CAPA (820.100) + supplier controls (820.50) + production + process controls (820.70).
• PMA supplement misclassification — significant change implemented under annual report when 180-day supplement was required.
• Annual report content thin — change summaries missing or insufficient; literature surveillance not documented.
• Post-approval study delay — milestone non-compliance triggering FDA escalation including potential Order modification.
• MDR reporting lapse — death / serious-injury reports past the §803 deadline; this is the single most common Warning Letter trigger for PMA-holders.
• UDI / GUDID data quality — incomplete or inaccurate UDI records; recurring item in CDRH UDI surveillance.
• Labelling change implemented without supplement — particularly for IFU updates affecting indications or contraindications.
• QMSR transition gaps — design-controls programme not fully aligned with ISO 13485:2016 + the 2024 final-rule expectations by the 2 Feb 2026 effective date.

• IDE-study enrolment progress vs plan; site activation rate; protocol-deviation rate.
• Pre-Submission engagement count per pre-PMA development programme.
• PMA filing acceptance rate (RTF avoided).
• Major-deficiency letter count + cycle time on response.
• Time-from-submission-to-approval (calendar + FDA days).
• PAI outcome — 483 observation count + classification.
• Conditions-of-approval count + post-approval study on-time milestone rate.
• PMA supplement count by type + cycle time vs MDUFA goal.
• Annual report on-time filing.
• MDR reporting on-time rate + lookback audit pass rate.
• UDI + GUDID data-quality score.
• Recall rate + Class I recall count.
• Post-approval study completion rate vs commitment timeline.

V5 Ultimate treats PMA as the highest-rigour end of the medical-device workspace. The design history file (DHF) per 21 CFR 820.30 is structured to map directly into the PMA dossier sections: device description + intended use into the cover sections, design verification + validation evidence into the non-clinical + clinical sections, risk-management file per ISO 14971 into the risk-analysis section, software lifecycle artefacts per IEC 62304 + FDA software guidance, human-factors evidence per IEC 62366-1 + FDA HF guidance, biocompatibility evaluation per ISO 10993, sterilisation validation per ISO 11135 / 17665. The IDE study-management overlay tracks clinical-site activation, subject enrolment, IRB approvals, monitoring visits, protocol deviations, adverse-event reporting timelines + sponsor-monitoring responsibilities per Part 812.

Pre-approval inspection (PAI) readiness is operationalised through the QSR / QMSR workspace: design controls + production + process controls + CAPA + management responsibility + supplier controls + facilities + equipment all in audit-ready state with the QMSR transition (effective 2 Feb 2026) tracked as a programmatic project. PMA supplement routing reads the proposed-change attributes (design, manufacturing, labelling, indication) and the FDA 2008 PMA-supplement decision-making framework to recommend supplement type (panel-track / 180-day / real-time / CBE / 30-day notice / annual report) with the rationale documented + the dossier section being modified linked. Conditions-of-approval are first-class records with the post-approval-study commitment tracked against the Order milestones.

Lifecycle obligations are wired together: MDR reporting per 21 CFR Part 803 surfaces from complaint + adverse-event records with the clock + reportability decision logged + the QA + RA review steps captured + the submission timestamp audit-trailed; UDI + GUDID submission tracks each device version + model with GUDID data-quality validation; corrections + removals + recall management per Parts 806 + 7 routes through a structured workflow. The annual report per 21 CFR 814.84 is auto-assembled from the year's PMA-supplement filings, annual-report-eligible changes, deviations, study summaries, literature surveillance + label history with cross-reference checks. Every PMA artefact carries audit-trail evidence per 21 CFR 11 / Annex 11 and renders into the regulatory bundle on demand.